(NASDAQ: INO) Inovio Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.99%.
Inovio Pharmaceuticals's revenue in 2026 is $0.On average, 7 Wall Street analysts forecast INO's revenue for 2026 to be $1,150,015,307, with the lowest INO revenue forecast at $0, and the highest INO revenue forecast at $3,586,784,040. On average, 6 Wall Street analysts forecast INO's revenue for 2027 to be $5,145,285,969, with the lowest INO revenue forecast at $838,528,832, and the highest INO revenue forecast at $10,572,110,955.
In 2028, INO is forecast to generate $10,934,113,197 in revenue, with the lowest revenue forecast at $5,135,989,093 and the highest revenue forecast at $17,561,222,438.